Health Care & Life Sciences » Biotechnology | Puma Biotechnology Inc.

Puma Biotechnology Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
83,948.00
141,327.00
215,889.00
229,476.00
81,698.00
165,421
Total Accounts Receivable
9,813.00
1,760.00
-
-
9,670.00
21,948
Inventories
-
-
-
-
2,029.00
2,625
Other Current Assets
2,635.00
6,292.00
7,660.00
6,998.00
12,997.00
13,009
Total Current Assets
96,396.00
149,379.00
223,549.00
236,474.00
106,394.00
203,003
Net Property, Plant & Equipment
1,684.00
2,157.00
2,383.00
5,153.00
4,470.00
3,963
Total Investments and Advances
1,214.00
1,215.00
4,313.00
4,317.00
4,317.00
4,319
Intangible Assets
-
-
-
-
48,355.00
44,408
Other Assets
5,080.00
10,007.00
9,597.00
6,846.00
1,989.00
3,429
Total Assets
104,374.00
162,758.00
239,842.00
252,790.00
165,525.00
259,122
Accounts Payable
10,692.00
14,997.00
-
20,035.00
27,692.00
Other Current Liabilities
8,579.00
29,444.00
32,442.00
17,426.00
30,648.00
Total Current Liabilities
19,271.00
44,441.00
32,442.00
37,461.00
58,340.00
Long-Term Debt
-
-
-
-
48,477.00
Other Liabilities
1,116.00
1,269.00
1,393.00
5,505.00
5,406.00
Total Liabilities
20,387.00
45,710.00
33,835.00
42,966.00
112,223.00
Common Equity (Total)
83,987.00
117,048.00
206,007.00
209,824.00
53,302.00
Total Shareholders' Equity
83,987.00
117,048.00
206,007.00
209,824.00
53,302.00
Total Equity
83,987.00
117,048.00
206,007.00
209,824.00
53,302.00
Liabilities & Shareholders' Equity
104,374.00
162,758.00
239,842.00
252,790.00
165,525.00

About Puma Biotechnology

View Profile
Address
10880 Wilshire Boulevard
Los Angeles California 90024
United States
Employees -
Website http://www.pumabiotechnology.com
Updated 07/08/2019
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use.